• Publications
  • Influence
Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent
In this study, PK2 displayed a ∼5-fold reduction in cardiotoxicity relative to free DOX and this supported the progression of PK2 into early clinical investigation. Expand
Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule
Modification of the dosing schedule for doxorubicin (DOX) administration represents a possible method of reducing cardiotoxicity from this potent anti-cancer drug, while at the same time maintainingExpand
Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).
It was concluded that an oil containing GLA (So-1100) has similar cardioprotective properties against DOX-induced cardiotoxicity as ICRF-187, but with less general toxicity in this rat model. Expand